Welcome to our dedicated page for ANGIODYNAMICS SEC filings (Ticker: ANGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ANGIODYNAMICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ANGIODYNAMICS's regulatory disclosures and financial reporting.
AngioDynamics Inc. executive Warren Nighan Jr., SVP Quality and Regulatory, reported the sale of 23,370 shares of common stock on 2026-07-30. The reported price of $14.72 per share is a weighted average from multiple trades between $14.65 and $14.80. After this transaction, he directly holds 64,745 shares. The filing indicates the sale was not made under a Rule 10b5-1 trading plan.
AngioDynamics, Inc. is the subject of a notice covering a proposed sale of 23,370 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with an indicated aggregate value of $344,004.06 as of the filing data.
The shares relate to equity awards, including 10,949 restricted stock shares granted on 07/17/2020 and 12,421 performance share units granted on 08/12/2021, identified as securities to be sold by the issuer’s insider.
AngioDynamics Inc. executive Laura Piccinini, SVP International, reported vesting of performance share units granted on July 19, 2023. A target grant of 28,336 units resulted in 8,047 common shares being issued, while 4,506 shares were withheld at $13.82 per share for taxes and the remaining units were forfeited.
Warren Nighan Jr., SVP Quality and Regulatory at AngioDynamics, had a 2023 performance share unit grant settle. A target award of 20,052 performance share units led to the issuance of 5,694 shares of common stock based on performance, with the remaining units forfeited. Of the shares issued, 1,671 were withheld at $13.82 per share to satisfy tax withholding obligations.
AngioDynamics Inc EVP and CFO Stephen A. Trowbridge reported equity award activity related to performance share units granted on July 19, 2023. Based on performance metrics and relative total shareholder return, 16,296 shares of Common Stock vested and were issued from a 57,381-unit target grant, with the remaining units forfeited. To satisfy related tax withholding obligations, 8,319 shares were withheld at $13.82 per share.
AngioDynamics Inc. President and CEO James C. Clemmer reported the vesting and settlement of a performance share grant on July 22, 2026. A 2023 target grant of 184,361 performance share units was settled based on multi-year performance, resulting in issuance of 52,358 shares of Common Stock and forfeiture of the remaining units. Of the issued shares, 26,728 were disposed of at $13.8200 per share to satisfy tax withholding obligations, with the balance retained as directly owned common stock.
Chad Thomas Campbell, SVP/GM Vascular Access at AngioDynamics, reported the vesting of 6,466 shares of Common Stock on July 22, 2026, from performance share units granted July 19, 2023. A target of 22,768 performance share units could pay out 0–200%, with an additional 20% adjustment tied to relative total shareholder return over fiscal years 2024–2026; unearned units were forfeited. To cover tax withholding on the vesting, 2,330 shares were disposed at $13.82 per share.
REED JAN STERN reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. director Jan Stern Reed received a grant of 11,887 shares of common stock on July 15, 2026, reported at a price of $0.00 per share. A footnote explains this represents 11,887 restricted stock units granted as regular annual compensation for board service that immediately vested at grant. Following this award, Reed directly holds 116,921 common shares.
Licitra Karen A reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. director Karen A. Licitra received a grant of 11,887 shares of common stock on July 15, 2026, representing 11,887 restricted stock units as regular annual compensation for board service. These units immediately vested at grant, increasing her direct holdings to 102,322 shares.
JOHNSON WESLEY reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. director Wesley Johnson received a grant of 11,887 shares of common stock in the form of restricted stock units on 2026-07-15 as regular annual compensation for board service. The units immediately vested, bringing his directly held common shares to 155,425.